Page 459 - Essential Haematology

Index / 445

March haemoglobinuria 85 membrane protein band 3 protein monoclonal gammopathy of
marginal zone lymphomas 265–6 defi ciency, hereditary undetermined signifi cance
massive transfusion syndrome 340, spherocytosis 79 (MGUS) 273, 282, 283
360 menorrhagia 41, 44 monocytes 8, 109, 110, 111, 112,
mast cells 212 mental retardation, α-thalassaemia 114
mastocytosis 203, 212 92 function disorders 114–18
matriptase 2 mutation 46 mesenchymal stem cells 4–5 killing and digestion 114–15
mature B-cell neoplasms 254–5 metalloproteases 319, 337, 339 monocytosis 114–17, 120, 121
mature T-cell neoplasms 254–5 methaemoglobin reductase causes 117–18
May–Hegglin anomaly 116–17, defi ciency 22 monospot test 138
334 methaemoglobinaemia 21 MPL gene mutation, primary
mean cell volume (MCV) 27 methotrexate 63 myelofi brosis 210
iron defi ciency 34 methyl tetrahydrofolate 60, 61, 62, c-MPL receptors 316
neonates 416 63, 368 mucin-secreting adenocarcinoma
normal values 425 methylene tetrahydrofolate 382, 383
pregnancy 414 reductase (MTHFR) 67, disseminated intravascular
mean corpuscular haemoglobin 367, 368 coagulation 368
(MCH) microangiopathic haemolytic mucopolysaccharide disorders 117
normal values 425 anaemia 85, 86, 382, mucosa-associated lymphoid tissue
pregnancy 414 384 (MALT) lymphoma 154,
mean corpuscular haemoglobin microcytic, hypochromic anaemia 265
concentration (MCHC) 27, 34 multiple myeloma 273–4, 275,
iron defi ciency 34 autosomal recessive 46 276–8, 279, 280–1
normal values 425 management 44 amyloid deposition 285
mediastinal mass see also iron defi ciency anaemia clinical features 274, 275, 276,
ALL 225, 226 microRNAs (miRNAs) 160 285
Hodgkin lymphoma 246, 250 middle cerebral artery, Doppler cytogenetics 278
megakaryocytes ultrasonography 419, diagnosis 273–4
fragments in essential 420 hyperglobulinaemia 342
thrombocythaemia 209 mitochondria, haem synthesis 20 hyperviscosity syndrome 285
platelet production 315–16, 317 mitogen-activated protein (MAP) immunophenotype 277
selective depression 333 kinase 8, 9, 10 laboratory fi ndings 276–8
megaloblastic anaemia 59–60, 61, mitosis 10 prognosis 281
62–7, 68, 69–71 MN antibodies 402 treatment 278, 280–1
biochemical basis 62, 63 monoclonal antibodies (MAbs) MYC oncogene, Burkitt lymphoma
bone marrow 67, 68 cold/warm autoimmune 268
causes 59, 62 haemolytic anaemias Mycoplasma pneumoniae 389
clinical features 65–7 84 mycosis fungoides 257, 270
diagnosis 67, 69 see also named MAbs; rituximab myelin, defective methylation 67
DNA synthesis defects 71 monoclonal B-cell lymphocytosis myeloblasts 110
laboratory fi ndings 67, 68 (MBL) 235–7, 238, myelocytes 110
macrocytes 67, 72 239–41 myelodysplasia 215–22
malabsorption 65–6 clinical features 235–6 classifi cation 215, 216
tests for cause 69 disease course 241 clinical features 216–17
transcobalamin defi ciency 60 laboratory fi ndings 236–7, 238 cytogenetic abnormalities 216,
treatment 69–71 prognostic markers 237, 239 219
melanin pigmentation, vitamin B 12 staging 239 diagnosis 219, 220
defi ciency 66, 67 treatment 239–41 genetic abnormalities 155